A comprehensive guide to Hodgkin Lymphoma. Learn about Reed-Sternberg cells, symptoms, PET-CT staging, and immunotherapy options at Turkey Healthcare Group.
Everything You Need to Know About Hodgkin Lymphoma: From Symptoms to the Latest Immunotherapy and Targeted Treatments
Cancer is a formidable adversary in modern medicine. It is not a single disease but a group of disorders characterized by uncontrolled growth and abnormal spread of cells. Among more than 100 different types of cancer, those that arise in the blood and lymphatic system, collectively known as hematologic malignancies, represent a unique set of challenges and, in many cases, remarkable success stories in treatment.
Hodgkin lymphoma (HL), once considered a fatal diagnosis, is now regarded as one of oncology’s greatest success stories, with cure rates exceeding 80% for most patients. This article provides a comprehensive overview of Hodgkin lymphoma, from its history and biology to its clinical presentation, diagnostic methods, modern treatment strategies, and the long-term survivorship journey. At Turkey Healthcare Group, we walk beside our patients at every stage of this journey.
A Historical Overview: How Did Our Understanding of the Disease Evolve?
The story of Hodgkin lymphoma is closely linked to the English physician Dr. Thomas Hodgkin. In 1832, he presented a paper to the Medical and Chirurgical Society of London titled “On Some Morbid Appearances of the Absorbent Glands and Spleen.” In this pioneering work, he described seven patients who suffered from progressive, painless enlargement of the lymph nodes and spleen that ultimately led to death. At the time, the cause was unknown, and the condition was considered a mysterious illness.
For decades, Hodgkin’s observations were largely forgotten, and the disease was often confused with inflammatory or infectious disorders. At the end of the 19th century, physician Dorothy Reed, later Reed-Mendenhall, made a major breakthrough while working at Johns Hopkins Hospital. In 1902, she identified a distinctive giant cell within diseased lymph nodes that was not caused by inflammation but represented the malignant cell itself. This cell, now known as the Reed–Sternberg cell, became the defining pathological hallmark of the disease, which was later named Hodgkin’s disease in honor of its original discoverer.
The true transformation from a fatal condition to a highly curable disease began in the mid-20th century. The development of radiation therapy in the 1950s and 1960s, followed by the emergence of combination chemotherapy in the 1970s, most notably the ABVD regimen, revolutionized treatment. Today, Hodgkin lymphoma stands as a testament to the remarkable progress of modern medicine and a beacon of hope for patients worldwide.
What Is the Lymphatic System?
To understand Hodgkin lymphoma, one must first understand the lymphatic system—a complex network of vessels, tissues, and organs that forms a cornerstone of the immune system. Its primary functions include maintaining fluid balance, absorbing fats from the digestive system, and most importantly, defending the body against infection and disease.
Key components of the lymphatic system include:
- Lymph: A clear fluid that carries white blood cells, waste products, and foreign invaders.
- Lymph nodes: Small, bean-shaped filters located in the neck, armpits, chest, abdomen, and groin.
- Lymphocytes: A type of white blood cell, including:
- B cells: Produce antibodies.
- T cells: Directly attack infected or cancerous cells.
- Other organs: The spleen, thymus gland, tonsils, and bone marrow.
Hodgkin lymphoma arises from a lymphocyte—most commonly a B cell—that undergoes a series of genetic mutations. As a result, it loses its normal function and begins dividing uncontrollably, forming a tumor within a lymph node.
The Hallmark of the Disease: The Reed–Sternberg Cell
The defining pathological feature of classical Hodgkin lymphoma is the presence of the Reed–Sternberg (RS) cell. This large, abnormal cell—often containing two nuclei—originates from a B lymphocyte.
Interestingly, these malignant cells are extremely rare, making up less than 1% of the cells in an affected lymph node. The vast majority are normal immune cells recruited by complex chemical signals released by RS cells, creating an inflammatory environment that supports tumor survival and immune evasion.
Types of Hodgkin Lymphoma
The disease is divided into two main categories, both thoroughly evaluated within our specialized medical departments:
1. Classical Hodgkin Lymphoma (cHL)
Accounts for about 95% of cases and includes four histological subtypes:
- Nodular sclerosis (NSCHL): The most common, especially in young adults.
- Mixed cellularity (MCCHL): More common in older adults and patients with HIV.
- Lymphocyte-rich (LRCHL).
- Lymphocyte-depleted (LDCHL): Rare and more aggressive.
2. Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
A rare form (about 5%) characterized by “popcorn cells” rather than Reed–Sternberg cells and typically follows a more indolent course.
Who Is Most at Risk?
Hodgkin lymphoma has a distinctive bimodal age distribution:
- First peak: ages 15–35 years
- Second peak: after age 55
Risk factors include:
- Epstein–Barr virus (EBV) infection
- Weakened immune system (such as HIV infection or immunosuppressive therapy)
- Family history, particularly having a sibling or identical twin with the disease
What Are the Symptoms of Hodgkin Lymphoma?
Symptoms may be subtle at first and are often mistaken for common illnesses such as influenza or minor infections. The classic signs are known as “B symptoms,” which are important for diagnosis and disease staging.
1. Painless lymph node enlargement
This is the most common symptom and appears as painless swelling in one or more lymph node groups, often in the:
- Neck
- Above the collarbone
- Armpits
A large chest mass may cause:
- Cough
- Shortness of breath
- A feeling of fullness or pressure
2. B symptoms
- Fever: Recurrent unexplained fevers not related to infection
- Night sweats: Severe enough to require changing clothes or bedding
- Unintentional weight loss: More than 10% of body weight within six months
3. Other general symptoms
- Persistent fatigue
- Generalized itching without rash
- Pain in lymph nodes after alcohol consumption (rare but characteristic)
Most of these symptoms are nonspecific and may occur in many conditions, but persistent painless lymph node swelling—especially when accompanied by these symptoms—should prompt medical evaluation by professional doctors.
How Is Hodgkin Lymphoma Diagnosed?
The diagnosis of Hodgkin lymphoma follows several steps, beginning with clinical suspicion and ending with direct pathological confirmation.
1. Physical Examination
The physician examines lymph nodes in different parts of the body, evaluates the size of the liver and spleen, and looks for other possible signs of the disease.
2. Blood Tests
Blood tests cannot confirm the diagnosis, but they help assess the patient’s overall health, liver and kidney function, and signs of inflammation or anemia. An elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) may be detected.
3. Imaging Studies
Imaging plays a crucial role in determining how far the disease has spread (staging).
A. PET-CT: The Gold Standard
This is the most important imaging test for lymphoma, combining a PET scan (detects active cancer cells using a radioactive sugar tracer) and a CT scan (provides detailed anatomical images). PET-CT is used both for staging and for monitoring treatment response.
B. Additional Imaging When Needed
In certain cases, doctors may also use MRI scans or CT scans of the chest, abdomen, and pelvis utilizing the latest medical technologies.
4. Biopsy: The Definitive Test
A final diagnosis can only be made by examining tissue from an affected lymph node.
- Needle biopsy is often insufficient because it may not show the full lymph node structure.
- Excisional biopsy (removal of an entire lymph node) is preferred.
A pathologist examines the tissue under a microscope and performs specialized immunohistochemical tests to identify Reed–Sternberg cells and determine the lymphoma subtype.
How Is Hodgkin Lymphoma Staged?
After confirming the diagnosis, the next step is staging the disease using the Lugano classification.
Disease Stages
- Stage I: Involvement of one lymph node region or one extralymphatic organ (IE).
- Stage II: Two or more lymph node regions on the same side of the diaphragm (II), possibly with nearby organ involvement (IIE).
Our multidisciplinary team accurately evaluates advanced cases across our dedicated hospitals:
- Stage III: Lymph node involvement on both sides of the diaphragm (III), possibly including the spleen (IIIS) or a nearby organ (IIIE).
- Stage IV: Widespread spread to organs outside the lymphatic system such as bone marrow, liver, or lungs.
Stage Modifiers
- A or B: Absence or presence of B symptoms.
- X: Bulky disease (large chest mass or tumor ≥10 cm).
- E: Direct spread to a nearby organ.
Prognostic Factors: Predicting the Course of the Disease
In addition to stage, several factors influence prognosis and treatment intensity, including: Age over 45, Male sex, Low blood albumin, Anemia (low hemoglobin), High white blood cell count, and Low lymphocyte count. These factors are combined in the International Prognostic Score (IPS) to classify patients into low risk, intermediate risk, or high risk.
What Are the Treatment Options for Hodgkin Lymphoma?
The primary goal of treatment is complete cure, while the secondary goal is minimizing long-term side effects. Treatment varies depending on stage, risk factors, age, and overall health. Patients can access personalized treatment packages tailored to their specific subcategory.
1. Chemotherapy (The Foundation of Treatment)
ABVD Regimen
The most commonly used regimen, given in multiple cycles. It is highly effective with manageable side effects.
Other Regimens
- A-AVD (Brentuximab + AVD): An alternative to ABVD in stages III–IV due to higher effectiveness and less lung toxicity.
- BEACOPP: A very intensive regimen with higher risks of serious side effects such as infertility and secondary cancers. It is often used in Europe for high-risk patients.
2. Radiation Therapy
Modern radiation therapy uses precise, low-dose techniques called ISRT (Involved-Site Radiation Therapy) and is typically given after chemotherapy to the most affected areas. Goals include improving disease control and reducing risks of heart complications and secondary cancers that were common with older wide-field radiation techniques.
Immunotherapy and Targeted Therapy in Hodgkin Lymphoma
These therapies represent one of the fastest-growing areas in Hodgkin lymphoma treatment, offering more precise targeting and fewer side effects than traditional chemotherapy.
1. Brentuximab Vedotin (Adcetris): A Smart Targeted Therapy
This is an antibody-drug conjugate that combines an antibody with chemotherapy.
- The antibody targets the CD30 protein on Reed–Sternberg cells.
- It delivers chemotherapy directly to cancer cells like a “smart bomb,” reducing damage to healthy cells.
- Used as part of first-line treatment in advanced disease (A-AVD regimen).
- A key therapy for relapsed or refractory Hodgkin lymphoma.
2. Immune Checkpoint Inhibitors
Examples include Nivolumab and Pembrolizumab. Reed–Sternberg cells exploit immune “brakes” such as the PD-1 pathway to avoid detection. Checkpoint inhibitors block these brakes, enable T cells to recognize and attack cancer cells, and show remarkable effectiveness in patients whose disease has relapsed after multiple treatments.
Treatment According to Disease Stage
Early Stages (I–II) – Favorable
Typical treatment includes 2 cycles of ABVD chemotherapy followed by short-course ISRT radiation. In very low-risk cases, 4–6 cycles of chemotherapy alone may be sufficient to avoid radiation.
Early Stages (I–II) – Unfavorable
Examples include B symptoms or bulky disease. Treatment usually includes 4 cycles of ABVD or A-AVD followed by ISRT radiation.
Advanced Stages (III–IV)
Standard treatment now often combines immunotherapy and chemotherapy, precisely through 6 cycles of A-AVD. Six cycles of ABVD remain an acceptable alternative but may be slightly less effective.
Relapsed or Refractory Disease: A New Chance for Cure
Despite high cure rates, about 10–15% of patients either do not respond to initial therapy (refractory disease) or experience a return of the disease after remission (relapsed disease). The encouraging news is that cure remains possible even after relapse.
1. Salvage Chemotherapy
More intensive drug combinations are used, including Ifosfamide, Gemcitabine, and Vinorelbine. The goal is to bring the disease back into remission.
2. Autologous Stem Cell Transplant (ASCT)
This process involves collecting and freezing the patient’s own healthy stem cells, administering very high-dose chemotherapy to destroy cancer cells (and bone marrow), and reinfusing the stem cells to restore bone marrow function and restart blood cell production. This approach is highly effective in eliminating residual disease.
3. Options for Patients Not Eligible for Transplant
For patients who cannot undergo ASCT or relapse after transplant, brentuximab vedotin and checkpoint inhibitors provide modern, effective options. These therapies can achieve long-term disease control and, in some cases, functional cure.
Long-Term Survivorship: Life After Cure
Surviving Hodgkin lymphoma is a major achievement, but it marks the beginning of an important new phase. Some survivors may experience late effects of treatment, making long-term follow-up essential. You can consult with our medical teams seamlessly regarding survivorship via our Online Services.
Key elements of survivorship care include:
- Continuous health monitoring
- Regular medical checkups
- Prevention and early detection of complications
Major Long-Term Health Effects
1. Heart Disease
- Chest radiation may accelerate atherosclerosis and affect heart valves.
- Anthracyclines (such as Adriamycin) can damage heart muscle.
2. Secondary Cancers
New cancers may appear years later due to treatment-related DNA damage. Most common include:
- Breast cancer (in women who received chest radiation)
- Lung cancer
- Leukemia or myelodysplastic syndromes
3. Lung Toxicity
Drugs such as bleomycin and radiation may cause lung fibrosis and reduced respiratory capacity.
4. Hypothyroidism
Neck radiation may lead to permanent thyroid underactivity.
5. Infertility
Chemotherapy and pelvic radiation can affect fertility. Fertility preservation counseling is therefore essential, especially for young patients.
Follow-Up After Treatment
Long-term follow-up typically includes regular physical examinations, screening for secondary cancers (such as early breast imaging), cardiac monitoring (e.g., echocardiography), and pulmonary function tests. To learn more about our ongoing studies and clinical milestones, explore our Achievements and Medical Articles page.
Conclusion
Hodgkin lymphoma represents one of the greatest success stories in oncology: It has transformed from a fatal disease into a highly curable one. Advances in treatment reflect the modern shift toward precision medicine and less toxic, more targeted therapies. Ongoing research aims to reduce treatment intensity, integrate immunotherapy into first-line care, and improve options for relapsed disease.
As our understanding of Reed–Sternberg cell biology continues to grow, the path is being paved toward more effective and gentler treatments—not only for lymphoma, but for many other cancers. If you or a loved one requires a comprehensive diagnostic review or advanced therapy plan, please contact us today. For additional patient testimonies and updates, feel free to visit our online Media Center.
Frequently Asked Questions (FAQs) About Hodgkin Lymphoma
1. What is Hodgkin Lymphoma?
Hodgkin Lymphoma is a type of blood cancer that develops in the lymphatic system, which is part of the body’s immune framework. It originates when a lymphocyte undergoes abnormal genetic mutations and divides uncontrollably.
2. What is oncology’s greatest success story reference regarding Hodgkin Lymphoma?
Hodgkin Lymphoma is considered an oncological success story because it has transformed from a historically fatal diagnosis into a highly curable disease, with survival and cure rates now exceeding 80% for most patients.
3. What is a Reed-Sternberg cell?
The Reed-Sternberg cell is a large, abnormal giant cell, often containing two nuclei, that originates from a B lymphocyte. It is the defining pathological hallmark used to diagnose classical Hodgkin Lymphoma.
4. Do Reed-Sternberg cells make up the bulk of the lymphoma tumor?
No. Surprisingly, Reed-Sternberg cells make up less than 1% of the cells in an affected lymph node. The rest are normal immune cells recruited by chemical signals to create a supportive environment for the tumor.
5. What are the main types of Hodgkin Lymphoma?
It is divided into Classical Hodgkin Lymphoma (which makes up 95% of cases and includes nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted subtypes) and Nodular Lymphocyte-Predominant Hodgkin Lymphoma (5%).
6. What are the classic “B symptoms” of Hodgkin Lymphoma?
B symptoms consist of three classic signs: recurrent unexplained fevers, severe night sweats that drench clothes or bedding, and unintentional weight loss of more than 10% of body weight within six months.
7. Is a swollen lymph node from Hodgkin Lymphoma usually painful?
No. The most common presentation is a completely painless enlargement of one or more lymph node groups, most frequently located in the neck, above the collarbone, or in the armpits.
8. What is the unique age distribution for Hodgkin Lymphoma risk?
It exhibits a bimodal age distribution, meaning it peaks twice: first among young adults aged 15 to 35, and a second peak occurring in older adults after the age of 55.
9. What are the known risk factors for Hodgkin Lymphoma?
Prominent risk factors include prior infection with the Epstein-Barr Virus (EBV), a weakened immune system (such as from HIV or immunosuppressive medical therapies), and a family history of the disease.
10. Can a simple blood test diagnose Hodgkin Lymphoma?
No. While blood tests assess overall organ health, anemia, or markers of inflammation like ESR and CRP, they cannot confirm a diagnosis. A definitive diagnosis requires a lymph node biopsy.
11. Why is an excisional biopsy preferred over a needle biopsy for lymphoma?
An excisional biopsy removes the entire lymph node, which is preferred because a needle biopsy may not provide enough tissue to view the full cellular structure and confirm the subtype accurately.
12. What imaging test is considered the gold standard for staging lymphoma?
A PET-CT scan is the gold standard. It combines a PET scan to identify highly active cancer cells using a radioactive tracer with a CT scan for clear anatomical mapping.
13. How is Hodgkin Lymphoma staged?
It is staged from Stage I to Stage IV based on the Lugano classification, identifying whether the cancer involves a single node region (Stage I) or has spread widely to organs outside the lymphatic system like bone marrow or lungs (Stage IV).
14. What are modifiers like ‘X’ or ‘B’ in lymphoma staging?
Modifiers add specific detail: ‘B’ indicates the presence of B symptoms, ‘A’ means they are absent, and ‘X’ represents bulky disease, meaning a large chest mass or a tumor measuring 10 cm or greater.
15. What is the ABVD regimen?
ABVD is the foundation combination chemotherapy regimen widely used to treat Hodgkin Lymphoma. It is highly effective and delivered in multiple cycles with manageable side effects.
16. How does targeted therapy like Brentuximab Vedotin (Adcetris) work?
Brentuximab Vedotin is a smart antibody-drug conjugate. The antibody targets the CD30 protein specifically found on Reed-Sternberg cells, delivering chemotherapy directly to them like a smart bomb while sparing healthy tissue.
17. What role do immune checkpoint inhibitors play in treatment?
Inhibitors like Nivolumab and Pembrolizumab block the PD-1 pathway that cancer cells use to hide. By disabling these “immune brakes,” they allow the patient’s own T cells to recognize and attack the lymphoma.
18. Can Hodgkin Lymphoma still be cured if it relapses?
Yes. Even if the disease relapses or resists initial treatments, a cure is still highly achievable through salvage chemotherapy followed by an Autologous Stem Cell Transplant (ASCT).
19. What are the major long-term health risks for lymphoma survivors?
Late effects from historical treatments can include accelerated heart disease, secondary cancers (such as breast or lung cancer), permanent thyroid underactivity (hypothyroidism), lung fibrosis, and infertility.
20. Why select Turkey Healthcare Group for Hodgkin Lymphoma care?
Turkey Healthcare Group connects patients with the highest caliber oncology centers and specialists in Turkey, utilizing precise PET-CT staging, smart immunotherapies, and advanced stem cell transplant options.
Turkey Healthcare Group stands out with a team of distinguished medical experts in Turkey, who always strive to provide the best healthcare services to patients.
If you are looking for exceptional healthcare or need medical consultation from top doctors, feel free to contact us.
We also invite you to view our leading medical staff and get to know their qualifications and experiences up close.
We are here to ensure you receive the best possible healthcare.
